These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 31519114)

  • 1. GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH).
    Alkhouri N; Lawitz E; Noureddin M; DeFronzo R; Shulman GI
    Expert Opin Investig Drugs; 2020 Feb; 29(2):135-141. PubMed ID: 31519114
    [No Abstract]   [Full Text] [Related]  

  • 2. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Lawitz EJ; Coste A; Poordad F; Alkhouri N; Loo N; McColgan BJ; Tarrant JM; Nguyen T; Han L; Chung C; Ray AS; McHutchison JG; Subramanian GM; Myers RP; Middleton MS; Sirlin C; Loomba R; Nyangau E; Fitch M; Li K; Hellerstein M
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1983-1991.e3. PubMed ID: 29705265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis.
    Matsumoto M; Yashiro H; Ogino H; Aoyama K; Nambu T; Nakamura S; Nishida M; Wang X; Erion DM; Kaneko M
    PLoS One; 2020; 15(1):e0228212. PubMed ID: 31990961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
    Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
    Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
    Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
    J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
    Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
    Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate.
    Dandan M; Han J; Mann S; Kim R; Li K; Mohammed H; Chuang JC; Zhu K; Billin AN; Huss RS; Chung C; Myers RP; Hellerstein M
    J Lipid Res; 2023 Mar; 64(3):100339. PubMed ID: 36737040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
    Vijayakumar A; Okesli-Armlovich A; Wang T; Olson I; Seung M; Kusam S; Hollenback D; Mahadevan S; Marchand B; Toteva M; Breckenridge DG; Trevaskis JL; Bates J
    Hepatol Commun; 2022 Sep; 6(9):2298-2309. PubMed ID: 35735253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated de novo lipogenesis, slow liver triglyceride turnover, and clinical correlations in nonalcoholic steatohepatitis patients.
    Lawitz EJ; Li KW; Nyangau E; Field TJ; Chuang JC; Billin A; Wang L; Wang Y; Huss RS; Chung C; Subramanian GM; Myers RP; Hellerstein MK
    J Lipid Res; 2022 Sep; 63(9):100250. PubMed ID: 35835205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
    Neokosmidis G; Cholongitas E; Tziomalos K
    World J Gastroenterol; 2021 Oct; 27(39):6522-6526. PubMed ID: 34754150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the Benefit/Risk of Acetyl-CoA Carboxylase Inhibitors through Liver Targeting.
    Huard K; Smith AC; Cappon G; Dow RL; Edmonds DJ; El-Kattan A; Esler WP; Fernando DP; Griffith DA; Kalgutkar AS; Ross TT; Bagley SW; Beebe D; Bi YA; Cabral S; Crowley C; Doran SD; Dowling MS; Liras S; Mascitti V; Niosi M; Pfefferkorn JA; Polivkova J; Préville C; Price DA; Shavnya A; Shirai N; Smith AH; Southers JR; Tess DA; Thuma BA; Varma MV; Yang X
    J Med Chem; 2020 Oct; 63(19):10879-10896. PubMed ID: 32809824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
    Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M
    J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice.
    Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ
    Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH).
    Sivakumar P; Saul M; Robinson D; King LE; Amin NB
    Sci Rep; 2024 Jul; 14(1):17072. PubMed ID: 39048608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenofibrate Mitigates Hypertriglyceridemia in Nonalcoholic Steatohepatitis Patients Treated With Cilofexor/Firsocostat.
    Lawitz EJ; Bhandari BR; Ruane PJ; Kohli A; Harting E; Ding D; Chuang JC; Huss RS; Chung C; Myers RP; Loomba R
    Clin Gastroenterol Hepatol; 2023 Jan; 21(1):143-152.e3. PubMed ID: 34999207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents.
    Goedeke L; Bates J; Vatner DF; Perry RJ; Wang T; Ramirez R; Li L; Ellis MW; Zhang D; Wong KE; Beysen C; Cline GW; Ray AS; Shulman GI
    Hepatology; 2018 Dec; 68(6):2197-2211. PubMed ID: 29790582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia.
    Morrow MR; Batchuluun B; Wu J; Ahmadi E; Leroux JM; Mohammadi-Shemirani P; Desjardins EM; Wang Z; Tsakiridis EE; Lavoie DCT; Reihani A; Smith BK; Kwiecien JM; Lally JSV; Nero TL; Parker MW; Ask K; Scott JW; Jiang L; Paré G; Pinkosky SL; Steinberg GR
    Cell Metab; 2022 Jun; 34(6):919-936.e8. PubMed ID: 35675800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and Safety of Firsocostat, an Acetyl-Coenzyme A Carboxylase Inhibitor, in Participants with Mild, Moderate, and Severe Hepatic Impairment.
    Younis IR; Nelson C; Weber EJ; Qin AR; Watkins TR; Othman AA
    J Clin Pharmacol; 2024 Jul; 64(7):878-886. PubMed ID: 38520128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting ACC for NASH resolution.
    Zhang XJ; Cai J; Li H
    Trends Mol Med; 2022 Jan; 28(1):5-7. PubMed ID: 34844875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.